CIK 0001211583
- Non-accelerated filer
- Smaller reporting company
FENNEC PHARMACEUTICALS INC.
Sign in to watch- Ticker
- FENC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- Phone
- +1 919-636-4530
- Business address
- PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
- Former names
- ADHEREX TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,550,718
- in 5 filings, $1.4M under 10b5-1 plans
Net −$1,550,718. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-15 | Haigh Adrian CHIEF OPERATING OFFICER | Sale 10b5-1 | −22,222 | $10.30 | $229K | 22,222 |
| 2024-04-15 | RALLIS CHRIS A Director | Sale 10b5-1 | −800 | $10.45 | $8K | 44,449 |
| 2024-04-05 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −44,300 | $10.75 | $476K | 187,471 |
| 2024-04-04 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −14,583 | $10.89 | $159K | 261,471 |
| 2024-04-04 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −29,700 | $10.89 | $324K | 231,771 |
| 2024-04-03 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −14,584 | $10.78 | $157K | 302,054 |
| 2024-04-03 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −26,000 | $10.78 | $280K | 276,054 |
| 2024-03-26 | RALLIS CHRIS A Director | Sale 10b5-1 | −2,114 | $10.97 | $23K | 40,920 |
| 2024-03-26 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale | −13,975 | $10.90 | $152K | 91,771 |
| 2024-03-25 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −13,975 | $11.00 | $154K | 105,746 |
| 2024-01-05 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −15,000 | $10.41 | $156K | 119,721 |
| 2024-01-04 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −15,000 | $10.64 | $160K | 134,721 |
| 2023-12-28 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale | −3,656 | $11.55 | $42K | 287,471 |
| 2023-12-26 | RALLIS CHRIS A Director | Sale 10b5-1 | −1,390 | $10.90 | $15K | 44,788 |
| 2023-11-20 | RALLIS CHRIS A Director | Sale 10b5-1 | −269 | $8.25 | $2K | 43,034 |
| 2023-11-08 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale | −17,049 | $7.69 | $131K | 290,582 |
| 2023-11-08 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Sale | −7,995 | $7.90 | $63K | 282,587 |
| 2023-08-18 | RALLIS CHRIS A Director | Sale 10b5-1 | −673 | $7.85 | $5K | 43,303 |
| 2023-07-24 | RALLIS CHRIS A Director | Sale 10b5-1 | −6,796 | $8.17 | $56K | 43,976 |
| 2023-07-06 | RALLIS CHRIS A Director | Sale 10b5-1 | −2,207 | $8.47 | $19K | 28,826 |
Page 4 of 7 · 125 trades